Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG)

  • Brown T, Boland A, Bagust A, et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), November 2009

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • AstraZeneca

II) Professional/specialist and patient/carer groups:

  • British Thoracic Society (Lung Cancer and Mesothelioma Working Party)

  • Cancer Research UK

  • Macmillan Cancer Support

  • National Lung Cancer Forum for Nurses

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • Roy Castle Lung Cancer Foundation

  • UK Oncology Nursing Society

III) Other consultees:

  • Deparment of Health

  • Kirklees Primary Care Trust

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • British Thoracic Oncology Group

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Eli Lilly

  • Medac

  • NHS Quality Improvement Scotland

  • Pierre Fabre

  • Sanofi Aventis

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on gefitinib by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Mike Lind, Consultant Medical Oncologist, Castle Hill Hospital, nominated by the Royal College of Physicians – clinical specialist

D. Representatives from the following manufacturer/sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • AstraZeneca

  • National Institute for Health and Care Excellence (NICE)